The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study
Saudi Medical Journal · 2026
DOI: 10.15537/1658-3175.8778 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Saudi Medical Journal, 2026. Verfasst von Maha H Jamal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Immunoglobulin Fc Fragments. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study aimed to evaluate the effectiveness and safety of dulaglutide in individuals with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).
Methods
This retrospective cohort study included 212 patients with CKD (stages 1–4) and T2DM treated with once-weekly dulaglutide (1.5 mg) for either 12 or 24 months at three tertiary care centers in Saudi Arabia from January 2021 to December 2023. Safety was assessed based on the presence of adverse events. Efficacy was measured using the changes in estimated glomerular filtration rate (eGFR), glycated hemoglobin (HbA1c), and body mass index (BMI). Changes in efficacy outcomes were assessed using paired t-tests.
Results
Baseline HbA1c was 9.1% (± 1.8%), BMI was 33.0 (± 6.4) kg/m2, and eGFR was 68.2 (± 28.5) mL/min/1.73 m2. At 12 and 24 months, HbA1c decreased by 1.2% (95% confidence interval [CI]: 1.0–1.4, p < 0.001) and BMI by 1.1 kg/m2 (95% CI: 0.9–1.3, p < 0.001). Further, eGFR remained stable at 12 months (change: -0.1, 95% CI: -2.2 to 2.0, p = 0.937) but increased by 2.8 mL/min/1.73 m2 (95% CI: 0.3–5.3, p = 0.029) at 24 months, particularly in stage 3 CKD (p = 0.041). By multivariable regression analysis, with adjustment for concomitant medications, dulaglutide was associated with a significant increase in eGFR increase at 24 months (adjusted mean change: 2.6 mL/min/1.73 m2, 95% CI: 0.2–5.0, p = 0.034). Patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Ministry of Health, Saudi Arabia.
- Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Surgery, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
- Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
ORCID-Profile: Maha H Jamal, Hassan A Alzahrani, Duaa M Bakhshwin, Ranya A Ghamri, Fatmah S Binzomah, Wisam H Jamal, Moaz W Abulfaraj
Zitieren
APA
Jamal, M. H., Alzahrani, H. A., Bakhshwin, D. M., Ghamri, R. A., Binzomah, F. S., Jamal, W. H., & Abulfaraj, M. W. (2026). The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study. Saudi Medical Journal. https://doi.org/10.15537/1658-3175.8778
Vancouver
Jamal MH, Alzahrani HA, Bakhshwin DM, Ghamri RA, Binzomah FS, Jamal WH, et al. The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study. Saudi Medical Journal. 2026. doi:10.15537/1658-3175.8778
BibTeX
@article{Jamal2026,
author = {Jamal, Maha H and Alzahrani, Hassan A and Bakhshwin, Duaa M and Ghamri, Ranya A and Binzomah, Fatmah S and Jamal, Wisam H and Abulfaraj, Moaz W},
title = {The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study},
journal = {Saudi Medical Journal},
year = {2026},
doi = {10.15537/1658-3175.8778}
}
EUVIMED